CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
about
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationNanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.The use of immunotherapy in the treatment of melanomaThe "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccinesProtEx technology for the generation of novel therapeutic cancer vaccinesCD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challengeCombined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.DNA/MVA Vaccines for HIV/AIDSImmune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.Prospects for CD40-directed experimental therapy of human cancer.Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapyProtection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors.Targeting the tumor microenvironment to enhance antitumor immune responsesImmune checkpoint blockade and interferon-α in melanoma.Direct Interaction of CD40 on Tumor Cells with CD40L on T Cells Increases the Proliferation of Tumor Cells by Enhancing TGF-β Production and Th17 Differentiation.Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Using antibodies in tumour immunotherapy.ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine modelThe tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome.Immunotherapy of cancer in 2012.Dendritic cells: tools and targets for antitumor vaccination.SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccinesAgonistic CD40 antibodies and cancer therapy.CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation.Design and development of synthetic peptide vaccines: past, present and future.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivoActivation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.Molecular mechanism and function of CD40/CD40L engagement in the immune system.Immune regulatory antibodies: are they the next advance?Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulationAnti-VEGF antibody enhances the antitumor effect of CD40.A CD40/CD40L feedback loop drives the breakdown of CD8(+) T-cell tolerance following depletion of suppressive CD4(+) T cells.
P2860
Q27472925-ECA921F2-33F8-48BB-9FB3-0678430EE196Q28068378-F5152160-44B2-4DC0-AA3E-8BF29DB65AFEQ33509292-95EEE6EE-BC41-4C5B-A54D-119A92687F3DQ33586493-4F142605-D442-42A5-BB9C-14E0F55AF9E5Q33593858-5013BB87-B688-4686-A7F7-566D268E5DE0Q33736218-DDE0A076-4EBF-4A01-B811-DE3199C829CFQ33857971-CD4111BC-8A5F-4843-B0C0-6135B331E6A6Q34048819-EBC46EAF-DD6C-44CA-BB45-6A3AAFEC4AABQ34059531-180DED2C-CEE9-4861-A1B4-E1E8861A18CBQ34071227-B66F7945-4178-4BCA-B726-37472D0CECB2Q34457611-17015D0E-3E0C-4BF1-80D6-0C4A84409C3DQ34492802-E429CB6E-0CE3-4C21-BEDF-BEE9C153AA5DQ34616576-9898817E-8D23-46E7-A84E-D45A1F77117DQ35028895-A444E6B9-7E07-4ABB-B498-F0DA20757E98Q35119800-8C6748EC-7321-420E-99DD-4247A85DFB1EQ35130794-A674EA26-6972-43A0-88E5-D01961D6109EQ35176307-60E847BE-AE29-4813-8C1A-5EB355BBC304Q35598991-CBB9FE93-581C-44AD-8844-79FB4C564148Q35620726-F9A414C9-88D0-4B41-BB50-16721086D891Q35711576-B54C922F-F035-467B-A36D-BA10706C21AAQ35842612-AE246BEC-6812-4D0F-909F-933EF5766840Q36001701-03A0FE2E-A5E9-48BA-89BE-9F88C748C981Q36037271-C3A99661-03AE-47F8-9972-19569B29C1FFQ36050315-E76D409A-DA6B-4D95-941A-E753517DB262Q36243536-8E6DC8C0-0D93-419C-890B-5FA6D7E8BC80Q36284556-752ADAF0-8ED9-474D-B22A-0556D383AA39Q36487245-A8D3824E-7DF5-4ABD-A8E0-D582B2A28CDDQ36664195-2E117A53-0D83-42A8-A3BD-35A6C6F8B64FQ36671187-EA31743B-B9B7-4422-8DB4-7205DE6D92A6Q36899093-9A4DD593-4A13-4177-8C9F-588C85A7B2D8Q37029731-62E094D6-B91B-4FE8-88C9-01BB87DDEB5DQ37273700-89896704-08B9-4F29-BA33-989C19515FEBQ37386167-9A9811B1-EC43-4221-BB4D-F70DF59892F2Q37422374-B56D3354-2205-4683-80E6-2F63D15C81BCQ37474929-3CE3BA7F-F441-4582-84D5-09B9D2D16CDCQ37778691-B2AD1AF5-9321-46B0-B6E5-00FB975F01B2Q38221692-C479EDE3-7B5C-47BE-B7B3-E9D0B3D3A0F3Q38974641-1EB5A4EA-8827-49F5-8C7C-E0FEC555CB43Q39017783-25CD60A8-4331-4C0F-B02E-AD1C166B5903Q39034714-7B70E833-0EA2-43C2-9D84-A66D6C94A2DF
P2860
CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
CD40 stimulation leads to effective therapy of CD40
@nl
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@ast
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@en
type
label
CD40 stimulation leads to effective therapy of CD40
@nl
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@ast
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@en
prefLabel
CD40 stimulation leads to effective therapy of CD40
@nl
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@ast
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@en
P2093
P2860
P356
P1476
CD40 stimulation leads to effe ...... totoxic T lymphocyte immunity.
@en
P2093
Annemieke Th den Boer
Cornelis J M Melief
Ellen I H van der Voort
Geertje J D van Mierlo
Jan Paul Medema
Marieke F Fransen
Rene E M Toes
Rienk Offringa
P2860
P304
P356
10.1073/PNAS.082107699
P407
P577
2002-04-02T00:00:00Z